Objective
To examine the surgical and pathologic findings of 15 patients who had initially unresectable hepatocellular carcinoma (HCC) and received preoperative systemic chemoimmunotherapy and sequential resection.
Summary Background Data
More than 80% of patients with HCC present for treatment at an unresectable stage. Conventional treatment has produced a low tumor response rate in this group of patients. Recently, new systemic chemoimmunotherapy has been found to be effective and able to make previously unresectable HCC resectable. Sequential resection after response to chemoimmunotherapy could therefore induce complete clinical remission.
Methods
From July 1996 to February 1999, 150 patients with unresectable HCC were treated with systemic chemoimmunotherapy consisting of cisplatin, ␣-interferon, doxorubicin, and 5-fluorouracil for a maximum of six cycles. The residual tumors were reassessed for resectability after treatment aiming at complete remission in the patients after combined modality treatment. Twenty-seven patients had a more than 50% regression in tumor size (2 complete remissions, 25 partial remissions). Fifteen patients had resectable disease after treatment, and all underwent sequential resection with curative intent. Treatment outcome and the surgical and pathologic features of these 15 patients were studied.
Results
Fifteen of 150 patients responded to chemoimmunotherapy and underwent sequential resection. They were considered to have unresectable disease as a result of extensive local disease (with and without major vascular involvement) in 10 patients and the presence of extrahepatic or metastatic disease in 5 patients. All patients except two were hepatitis B carriers. Surgical resection of the residual lesion after chemoimmunotherapy was successful for all patients. Eight of the patients had complete pathologic remission. The rest had minimal residual disease (Ͻ5%) only. All 15 patients entered complete clinical remission after surgery. Thirteen patients were still alive as of this writing and two had died of recurrent disease. The 1-, 2-, and 3-year survival rates were 100%, 100%, and 53%, respectively. The mean follow-up period was 27 months (range 15-37). Neither the median disease-free nor overall survival had been reached. Ten patients remained in complete remission as of this writing.
Conclusion
Combined modalities with systemic chemoimmunotherapy and surgical resection can achieve complete clinical remission and long-term control of disease in patients with unresectable HCC.
Surgical resection for hepatocellular carcinoma (HCC) is the only treatment that can potentially cure the disease. However, the resection rate has always been low because of the advanced stage and the presence of severe cirrhosis at presentation. Resection rates of 9% to 27% have been reported. [1] [2] [3] Thus, most HCC patients have unresectable disease that is generally considered to be incurable, and the prognosis of these patients is dismal. Intraarterial chemotherapy with lipiodol 4 and transarterial chemoembolization (TACE) 5, 6 are widely practiced in the treatment of localized unresectable HCC, but these modalities have not been found to prolong survival in randomized studies. [7] [8] [9] [10] This may be because TACE is not as effective for large and diffuse types of HCC. 4 Patients with large HCC can rarely achieve complete remission by TACE alone. Conversion of unresectable to resectable disease is uncommon with TACE, except in one study from China. 11 Further, intraarterial treatment is in general not indicated in patients who have metastatic disease or a blocked portal venous system. Systemic chemotherapy is the only option for patients with unresectable HCC not suitable for intraarterial treatment. However, no systemic chemotherapy in HCC can so far provide a durable remission or convert unresectable disease to resectable. Since 1996, our center has been using a new systemic chemoimmunotherapy in the treatment of unresectable HCC. 12 Although the objective response rate was only 26%, 20% of the responding patients had significant tumor regression so that surgical resection was possible after chemoimmunotherapy. Ten percent of the patients even achieved complete pathologic remission with chemoimmunotherapy alone. Based on these preliminary results, all responding patients were considered for sequential resection, with the aim of producing complete clinical remission. In this article we report the radiologic, pathologic, and surgical findings of 15 patients with unresectable HCC treated with chemoimmunotherapy followed by surgery.
METHODS
From July 1996 to February 1999, 150 patients with unresectable HCC were treated with a systemic chemoimmunotherapy regimen comprising cisplatin (20 mg/m 2 , intravenous, day 1-4), ␣-interferon (5 MU/m 2 , subcutaneous, day 1-4), doxorubicin (40 mg/m 2 , intravenous, day 1), and 5-fluorouracil (400 mg/m 2 , intravenous, day 1-4). Treatment was repeated once every 3 to 4 weeks depending on the blood counts. Details of the chemoimmunotherapy regimen were the same as described in our earlier paper. 12 All patients had either a pretreatment ultrasound or computed tomography scan of the liver as baseline. Hepatic angiography was optional. Unresectable disease was defined as the presence of extrahepatic disease or extensive local disease not amenable to definitive resection. Disease with major vascular (portal or hepatic) invasion or the presence of thrombosis was considered unresectable. Response was assessed using the same imaging modality before treatment after three cycles of chemoimmunotherapy. Patients with an objective response, as evidenced by regression in tumor size or decreased serum ␣-fetoprotein (AFP) level, received a total of six cycles of chemoimmunotherapy. Another full staging workup was carried out after the full course of chemoimmunotherapy to assess the resectability of the residual lesion or lesions. Hepatic angiography was mandatory if the lesion remaining in the liver appeared to be resectable on the computed tomography scan or ultrasound. Surgical resection of the residual lesion was offered to patients if the procedure could potentially resect all gross lesions shown radiologically. The surgery was planned after the chemoimmunotherapy was completed and the patients had recovered from the therapy; the usual time was 2 months after the last dose of the chemoimmunotherapy.
Twenty-seven patients had a more than 50% reduction in tumor volume after six cycles of chemoimmunotherapy. Complete remission was seen in 2 patients and partial remission in 25 patients. Fifteen patients (14 partial remission and 1 less-than-partial remission) underwent surgery after chemoimmunotherapy. The rest of the responders did not undergo surgery because their disease was still considered to be unresectable even after chemoimmunotherapy. Treatment response and the surgical and pathologic findings of these 15 patients are reported here. All survival calculations were counted from the first day of chemoimmunotherapy.
Surgical procedures performed were right hepatectomy (n ϭ 8), left lateral segmentectomy (n ϭ 3), extended right hepatectomy (n ϭ 1), segment 5 resection (n ϭ 1), excision of omental tumor deposit (n ϭ 1), and right lower lung lobectomy (n ϭ 1). All patients underwent hepatectomy by means of a bilateral subcostal incision with xiphoid extension. Intraoperative ultrasonography was performed to study the tumor location and its margin as well as its relation to the portal structures and hepatic veins. Exposure to the posterior aspect of the right lobe and of the inferior vena cava was aided by strong costal traction with a Gray retractor. After complete mobilization of the whole liver, the extrahepatic portion of the right hepatic vein and the common trunk of the middle and left hepatic vein were exposed. In addition to the Pringle maneuver that secured hilar inflow control, a vascular clamp was selectively applied to the right or left and middle hepatic veins before the transection of liver parenchyma. A Cavitron ultrasonic aspirator (CUSA, Valleylab, Boulder, CO) was used to transect the liver parenchyma through the transection plane as determined by intraoperative ultrasonography. The goal was a 1-cm resection margin, but in some patients with gross macronodular cirrhosis and a shrunken liver, we accepted a lesser margin because the chemoimmunotherapytreated tumors usually had a thick fibrous capsule containing no viable tumor cells. In one patient, we enucleated the tumor from the main bifurcation of the porta hepatis because it was technically impossible to get a resection margin without damaging the porta hepatis structure. In another patient, we performed a left hemihepatectomy with a 1.1-cm margin and enucleated a "secondary tumor" in segment 6; on histologic section, however, the enucleated lesion showed no viable tumor cells.
RESULTS
Fifteen patients (10 men, 5 women) had received systemic chemoimmunotherapy and undergone sequential resection. The median age was 43 years (range 12-59). All except three patients had pretreatment percutaneous biopsy and confirmed HCC. The three patients who had no biopsy performed had serum AFP levels of 202,590, 93,330, and 316,300 ng/mL, and their tumor sizes were 12.4, 5.2, and 12.8 cm; all tested positive for hepatitis B. The stage of disease before treatment according to the American Joint Commission on Cancer classification was IIIA (n ϭ 3), IVA (n ϭ 8), and IVB (n ϭ 4). The median maximum diameter of the tumor was 7.4 cm (range 3.9 -22). All except two patients tested positive for hepatitis B; none of the patients tested positive for hepatitis C. Ten patients had a pretreatment serum AFP level of more than 200 ng/mL. The reasons for nonresectability were extensive local disease with main portal venous thrombosis or vascular invasion (n ϭ 4), extensive bilobar disease (n ϭ 6, presence of extrahepatic metastases (n ϭ 4), and both main portal vein thrombosis and extrahepatic disease (n ϭ 1). Fourteen patients had a partial remission (Ͼ50% reduction in tumor volume) after chemoimmunotherapy; one patient had a less-than-partial remission. Patient details are shown in Table 1 . Radiologic response (computed tomography scan and hepatic angiography findings) of one of the responders who had complete pathologic remission after chemoimmunotherapy is shown in Figure 1 .
Tolerance of chemotherapy in the 15 patients was good. The most common side effects are neutropenia and thrombocytopenia, which were reversible. Finger numbness and toe numbness were common symptoms after treatment as a result of peripheral neuropathy caused by cisplatin. One patient had a reactivation of hepatitis B after chemotherapy. Full recovery of the hepatitis after antiviral therapy was achieved before she underwent resection.
There were no in-hospital deaths after the liver resection. Surgical details are shown in Table 2 . Pathologic examination of the resected specimen showed either 100% (n ϭ 8) or more than 95% (n ϭ 7) necrosis. All patients had a clear histologic resection margin. Except for the two patients who underwent resection of extrahepatic metastases, all the local hepatic tumors that were resected had either a thick fibrous capsule or marked fibrosis in the rim of the tumor. One of the patients had a small satellite nodule in a radicle of a vein within the fibrous capsule seen on microscopic examination. Details of the pathologic findings are shown in Table 3 .
Thirteen patients were alive as of this writing (10 patients in remission, 3 patients with recurrent disease). Two patients (patients 1 and 2) had died of recurrent disease (35.5 and 31.1 months after surgery). The 1-, 2-, and 3-year survival rates were 100%, 100%, and 53%, respectively. The mean follow-up period was 27 months (range 15-37). Medians had not been reached for both disease-free and overall survival (Fig. 2) .
DISCUSSION
It is a generally accepted principle that cure for cancer is possible only if complete clinical remission can be achieved, with either one modality or combined modalities. This is seldom possible for unresectable HCC, making its prognosis dismal. Conventional intraarterial therapy (including intraarterial chemotherapy with or without lipiodolization and chemoembolization) for localized HCC may prolong survival in highly selected groups of patients but is seldom curative by itself. Conversion of unresectable dis- ease to resectable disease is not common with intraarterial therapy. Two prospective randomized studies 7, 8 found no survival benefit for TACE versus supportive care. In addition to localized disease, many patients have extrahepatic spread at presentation, and systemic chemotherapy is the only treatment option for them. To achieve complete clinical remission, it is common practice in our center to perform surgical resection for residual lesion after preoperative therapy if possible. Such an approach can induce complete remission and provide pathologic information about the tumor and its response to preoperative therapy. We reported earlier 13 the use of selective internal radiation treatment with intraarterial yttrium-90 microspheres for unresectable HCC; this enabled sequential resection in four patients with a pretreatment tumor size up to 16 cm. Three of these four patients had complete pathologic remission. In a retrospective study from Shanghai, 11 65 of 360 patients (18%) with unresectable HCC underwent sequential resection after responding to preoperative TACE. The degree of tumor necrosis was 40% to 100%. A study from the United States 14 described 14 patients with unresectable HCC who underwent combined radiation and chemotherapy followed by sequential resection. All the patients had more than 50% tumor reduction, but there was no mention of the histologic response to the systemic and radiation treatment.
The results of these three studies suggest that combined Compared with the Shanghai study, systemic therapy in our study had a higher pathologic remission rate: the tumor necrosis percentage was at least 95% in our study. The results of the five patients with extrahepatic disease at presentation were most encouraging. They were found to have an equally good response to the chemoimmunotherapy as those with disease confined to the liver. When we reported the first 50 patients in our phase II study using the same chemoimmunotherapy regimen, the resectability rate was 20%. 12 Therefore, looking at both studies, 11, 12 sequential resection after preoperative chemoimmunotherapy or TACE should be possible in approximately 18% to 20% of patients with unresectable HCC. The lower resectability rate after chemoimmunotherapy (15/150 [10%]) observed in the present study may be attributed to the inclusion of patients who failed to respond to previous treatment or developed postoperative recurrence.
Systemic therapy as a preoperative treatment for unresectable HCC has an additional benefit compared with intraarterial therapy or TACE. First, early control of systemic metastases is possible. Second, patients with blocked main portal veins who are not suitable for regional therapy can still be treated with systemic therapy. Five patients in this study had main portal venous thrombosis at presentation that resolved after systemic chemoimmunotherapy, making sequential resection possible. Pathologic examination of the resected lesions from this study showed a high degree of necrosis; some even formed a fibrous capsule. This makes sequential resection easier because the tumor is less vascular and it is easier to achieve a clear histologic resection margin.
In all 15 patients, even if there was a high degree of pathologic remission and tumor necrosis after systemic chemoimmunotherapy, there was always residual lesion seen on the computed tomography scan. Therefore, by conventional criteria, the best response that can be achieved is still a partial response, despite return to normal of the serum AFP level after treatment. There is obviously a discrepancy between conventional radiologic response criteria and pathologic response; this may undermine some effective drugs for HCC because no complete radiologic remission could be seen. This has implications for the evaluation of new drugs for HCC and shows that radiologic response criteria have limitations.
In summary, we found that preoperative systemic chemoimmunotherapy and sequential resection can induce complete clinical remission in patients with advanced unresectable HCC. Further research should examine the survival impact of such a combined approach compared with standard treatment in a prospective randomized study.
